Open Access. Powered by Scholars. Published by Universities.®

Digital Commons Network™

Open Access. Powered by Scholars. Published by Universities.®

Discipline
Institution
Keyword
Publication Year
Publication
Publication Type
File Type

Articles 258361 - 258390 of 1792275

Full-Text Articles in Entire DC Network

Sawyer Connect, February 2023, Sawyer Business School Feb 2023

Sawyer Connect, February 2023, Sawyer Business School

News and Updates from the Sawyer Business School

No abstract provided.


Human Immunodeficiency Virus (Hiv), Children's Mercy Kansas City Feb 2023

Human Immunodeficiency Virus (Hiv), Children's Mercy Kansas City

Clinical Pathways (Formally Known As Care Process Models)

No abstract provided.


Crossing The Jordan Together: Recoding The Language Of Discipleship Used Among The Tribes Of Jesus Followers, Brian D. Russell Feb 2023

Crossing The Jordan Together: Recoding The Language Of Discipleship Used Among The Tribes Of Jesus Followers, Brian D. Russell

Doctor of Ministry

This Project Portfolio addresses the following NPO: The post-pandemic era leaves many Christians and seekers unmotivated to re-engage with the church. Reconnection is possible by recoding discipleship as thriving, holistic devotional living. As a result of the Covid-19 pandemic, all churches, regardless of size and vitality prior to the pandemic, were dealing with the same challenges of re-engaging people in the church, especially within their hospitality teams. Therefore, an opportunity arose to bring churches together to find fresh ways to re-engage their faith community where no one is the perceived expert. I am currently an adjunct professor teaching undergraduate ministry …


Toward Wholeness: Discovering Intimacy With Jesus Through Holistic Healing, David H. Brown Feb 2023

Toward Wholeness: Discovering Intimacy With Jesus Through Holistic Healing, David H. Brown

Doctor of Ministry

NPO Statement: Christians longing for inner healing and wholeness along with growing intimacy with Jesus need a confident, competent pathway to follow.

Key Insights from Research: Intuitively true, but still surprising, the top factor for improving someone’s confidence in pursuing their healing and wholeness in a ministry setting is trust of the minister. This factor topped perceived competence of the minister, community support and biblical soundness as other confidence-building factors. Another key insight, this one brought about through my stakeholders, is the importance of telling one’s story, one’s testimony, to help gain trust and grow the confidence of a potential …


Reimagining The Church's New Member Experience Through Mutual Storytelling, Laura Holland Feb 2023

Reimagining The Church's New Member Experience Through Mutual Storytelling, Laura Holland

Doctor of Ministry

Most churches are great at welcoming visitors and have worked hard to develop their discipleship pipeline, but between these two stages where most churches focus and excel there is an experiential gap for new members. Looking into this gap more deeply, I discovered that despite guided assimilation processes, new church members feel abandoned when moved immediately to self-directed engagement. Providing for their unique needs increases their sense of belonging and commitment. Through conversations with church leaders, members, and those seeking to find church community, I noticed that this liminal period was the turning point in most of their stories, too …


Investigation Of Homocysteine, Vitamin B6 And Vitamin D Among Patients With Colorectal Cancer, Fenik A. Nadir, Zeyan A. Ali Feb 2023

Investigation Of Homocysteine, Vitamin B6 And Vitamin D Among Patients With Colorectal Cancer, Fenik A. Nadir, Zeyan A. Ali

Polytechnic Journal

Background and objectives: Colorectal cancer (CRC) is a disease that begins exclusively in the colon or rectum and is caused by the abnormal growth of glandular epithelial cells within the colon. Homocysteine, vitamin B6, and vitamin D are recognized to play a significant role in colorectal tumor pathogenesis. The aim of this study is to investigate serum levels of Hcy, vitamin D and vitamin B6 in colorectal cancer. Methods: The current study investigated the vital roles of homocysteine, vitamin B6 and vitamin D in cancer development by comparing serum levels of colorectal cancer patients with those of the healthy control …


Research On The Influence Of Management Practices On Hospital Performance: An Empirical Study Based On Hospitals In Eastern China, Zhihua Zhang Feb 2023

Research On The Influence Of Management Practices On Hospital Performance: An Empirical Study Based On Hospitals In Eastern China, Zhihua Zhang

Fordham Dissertations and Theses

Since the beginning of the 21st century, a series of challenges have been confronting global health development, including significant factors affecting human health such as population aging, severe infectious diseases, and climate change. In particular, the COVID-19 that swept the globe in the past three years has posed a major comprehensive test to the global health governance system. As both the last line of defense for human health and the largest consumer of health resources, how the hospital can "improve quality and promote efficiency" based on limited resources is the core of the first priority. Previous studies have proven that …


Synovial Sarcoma Of The Vulva: A Case Report And Literature Review With Discussion On Fertility Sparing Approaches, Gabriella Schoettle, Stephanie Gulstene, Jason Vickress, Akira Sugimoto, David D'Souza Feb 2023

Synovial Sarcoma Of The Vulva: A Case Report And Literature Review With Discussion On Fertility Sparing Approaches, Gabriella Schoettle, Stephanie Gulstene, Jason Vickress, Akira Sugimoto, David D'Souza

Obstetrics & Gynaecology Publications

No abstract provided.


Nonprofit Spotlight 2: Days For Girls International Feb 2023

Nonprofit Spotlight 2: Days For Girls International

Journal of Nonprofit Innovation

At Days for Girls International (DfG) we are turning periods into pathways. We increase access to menstrual care and education by developing global partnerships, cultivating social enterprises, mobilizing volunteers, and innovating sustainable solutions that shatter stigma and limitations for women and girls.


Speech/Language Impairment Or Specific Learning Disability? Examining The Usage Of Educational Categories, Lisa Archibald, Wendy C. Georgan, Tiffany Hogan Feb 2023

Speech/Language Impairment Or Specific Learning Disability? Examining The Usage Of Educational Categories, Lisa Archibald, Wendy C. Georgan, Tiffany Hogan

Data and Test Instruments

No abstract provided.


Association Between Measures Of Cognitive Function On Physical Function In Novice Users Of A Lower Limb Prosthesis, Humberto Omana, Courtney Frengopoulos, Manuel Montero-Odasso, Michael W. Payne, Ricardo Viana, Susan W. Hunter Feb 2023

Association Between Measures Of Cognitive Function On Physical Function In Novice Users Of A Lower Limb Prosthesis, Humberto Omana, Courtney Frengopoulos, Manuel Montero-Odasso, Michael W. Payne, Ricardo Viana, Susan W. Hunter

Physical Therapy Publications

BACKGROUND: Cognitive impairment is prevalent in people with lower limb amputations (PLLA) and is associated with adverse outcomes, such as falls and worse rehabilitation outcomes. Physical function tests are essential to examine abilities; however, no research in PLLA has clarified the magnitude of cognitive demands amongst available tests in users novice at walking with a prosthesis.

METHODS: People from inpatient prosthetic rehabilitation were recruited. Inclusion criteria were: age ≥ 50 years, unilateral transtibial amputation and able to walk independently. Gait velocity and the L Test under single-task (usual) and dual-task (walking while counting backwards) conditions assessed functional mobility. The Four …


Nonprofit Spotlight 3: Techcharities (Applied Technology Foundation) Feb 2023

Nonprofit Spotlight 3: Techcharities (Applied Technology Foundation)

Journal of Nonprofit Innovation

The mission of TechCharities is to help low-income families build technical skills and confidence by providing computer resources and basic technical training as they move toward self-reliance.


Ol Woman Blong Wota (The Women Of The Water), Sandy Sur, Ashley Burgess, Maeve Mckenna, Catherine Grant Feb 2023

Ol Woman Blong Wota (The Women Of The Water), Sandy Sur, Ashley Burgess, Maeve Mckenna, Catherine Grant

World Music Textbook

The women of Leweton have been performing Water Music for international audiences since the founding of the Leweton Cultural Village in 2008, and have been practising this tradition for as long as they remember. The women performers who feature in this film are Denilla Frazer, Melinda Frazer, Jerolyn Frazer, Beverley Frazer, Cecilia Tingris, Cicilia Wari, Marie Sur, Sonrin Sur, Trisha Sur, and Margaret Tingris.


Campus Housing Finance Authority Board Of Directors Meeting - Open Session Packet 02/01/2023, Uc Hastings Board Of Directors Feb 2023

Campus Housing Finance Authority Board Of Directors Meeting - Open Session Packet 02/01/2023, Uc Hastings Board Of Directors

2023 Board of Directors Agenda and Materials

No abstract provided.


Commonwealth Times 2023-02-01 Feb 2023

Commonwealth Times 2023-02-01

Commonwealth Times, 1969-

No abstract provided.


The Measurement Of Gender Expression In Survey Research, Dana Garbarski Feb 2023

The Measurement Of Gender Expression In Survey Research, Dana Garbarski

Sociology: Faculty Publications and Other Works

Previous research on the survey measurement of sexual orientation, gender identity, and gender expression (SOGIE) often focuses on the measurement of identity, with comparably little research focused on gender expression as a key feature of how gender is lived and experienced. This study examines the reliability and validity of survey questions about gender expression in a 2-by-5-by-2 factorial experiment that varies the question order, type of response scale, and the order of gender presentation in the response scale.

The results indicate that the effect of which (side of the) scale is presented first on gender expression varies by gender for …


Comparative Evaluation Of Biased Agonists Sarcosine , D-Alanine -Angiotensin (Ang) Ii (Sd Ang Ii) And Sarcosine , Isoleucine -Ang Ii (Si Ang Ii) And Their Radioiodinated Congeners Binding To Rat Liver Membrane At Receptors, Natalia M. Noto, Yazmin M. Restrepo, Hong W. Pang, Filipe Stoyell-Conti, Crystal A. West, Robert C. Speth, Nova Southeastern University Feb 2023

Comparative Evaluation Of Biased Agonists Sarcosine , D-Alanine -Angiotensin (Ang) Ii (Sd Ang Ii) And Sarcosine , Isoleucine -Ang Ii (Si Ang Ii) And Their Radioiodinated Congeners Binding To Rat Liver Membrane At Receptors, Natalia M. Noto, Yazmin M. Restrepo, Hong W. Pang, Filipe Stoyell-Conti, Crystal A. West, Robert C. Speth, Nova Southeastern University

HPD Articles

Angiotensin II analogue and β-arrestin biased agonist TRV027 (Sarcosine , d-Alanine -Angiotensin (Ang) II; SD Ang II), developed by Trevena, Inc. in the early 2010s, brought hopes of a novel treatment for cardiovascular diseases, due to its ability to simultaneously cause signaling through the β-arrestin signaling pathway, while antagonizing the pathophysiological effects of Ang II mediated by the AT receptor G protein signaling cascades. However, a phase II clinical trial of this agent revealed no significant benefit compared to placebo treatment. Using I-Sarcosine , Isoleucine -Ang II ( I-SI Ang II) radioligand receptor competition binding assays, we assessed the relative …


Impacts Of Protected Areas On Respiratory Health In The Brazilian Amazon, Katrina Mullan Feb 2023

Impacts Of Protected Areas On Respiratory Health In The Brazilian Amazon, Katrina Mullan

University Grant Program Reports

There is growing interest in the connection between the conservation of ecosystems and human health. Protection of ecosystems is often presented by opponents to be in direct conflict with human values, on the grounds that it restricts economic opportunities. At the same time, human health is a universal value that cuts across political, economic, and social divisions. To date, the empirical evidence for the extent to which conservation or land-use policy can generate health improvements is minimal. This project contributed by focusing on one large-scale policy, Brazil’s Amazon biome Protected Area (PA) network. It provided funds for processing and analysis …


Our Pearls Matter: Pcos Through The Lens Of Women Of Color And White Women, Kimberley Sheri Miles Feb 2023

Our Pearls Matter: Pcos Through The Lens Of Women Of Color And White Women, Kimberley Sheri Miles

Master's Theses

The prevalence of PCOS is increasing and due to the associated health complications, it is important to understand how higher-risk populations (women of color) cope with said condition. Analyzing current symptom management and treatment could help develop more practical resources and treatment strategies to help improve healthcare expectations and quality of life.

Ten women aged 22-38 with PCOS participated in comprehensive individual interviews with goal-oriented, semi-structured questions. A 27-question survey was also completed. Sampling was continued until data saturation was reached. The data was analyzed using the grounded theory technique which codes emergent themes with keywords and phrases which ultimately …


Supporting Virtual Supervision As Part Of A Hybrid Workforce, Quality Improvement Center For Workforce Development Feb 2023

Supporting Virtual Supervision As Part Of A Hybrid Workforce, Quality Improvement Center For Workforce Development

QIC-Tips

More and more public child welfare agencies offer the opportunity to work in a hybrid environment, combining remote work with in-office work. This has raised questions among supervisors about how best to manage a remote workforce. Since research on virtual supervision is fairly limited relative to the popularity of remote work, studies are needed to understand the ways and conditions that influence effectiveness. Available research on remote work indicates that it is moderately associated with greater perceived autonomy and modestly associated with better supervisor relationships, performance, and job satisfaction. It was also modestly associated with decreased role stress and turnover …


Is That Route Really The Most Fuel-Efficient?, Mark Burris, Mahim Khan, Jeremy Johnson Feb 2023

Is That Route Really The Most Fuel-Efficient?, Mark Burris, Mahim Khan, Jeremy Johnson

Research Reports

Many travelers use Google Maps to select the route for their trip and the Google recommendation can have a significant impact on traffic congestion. Google recently added a new route option: the most fuel-efficient route. In theory, the algorithm behind this route selection (Route E) examines the current travel conditions on the available routes and estimates typical fuel consumption based on those conditions. This should include acceleration/deceleration events as these change of speed events significantly impact fuel consumption and are a critical aspect of selecting the most fuel-efficient route, especially when comparing freeway general purpose lanes (GPLs) to Express Lanes/Managed …


Efficacy And Safety Of Eptacog Beta (Recombinant Human Fviia) According To Age In Persons With Haemophilia A/B With Inhibitors Undergoing Surgical Procedures, W. Miesbach, M. Escobar, L. Boggio, S. Bonanad, G. Castaman, Y. Darguard, A. Giermasz, C. Hermans, Philip Kuriakose, D. Quon, M. Reding, D. Q. Tran, J. Windyga, D. Bonzo, C. Macie, J. Mahlangu Feb 2023

Efficacy And Safety Of Eptacog Beta (Recombinant Human Fviia) According To Age In Persons With Haemophilia A/B With Inhibitors Undergoing Surgical Procedures, W. Miesbach, M. Escobar, L. Boggio, S. Bonanad, G. Castaman, Y. Darguard, A. Giermasz, C. Hermans, Philip Kuriakose, D. Quon, M. Reding, D. Q. Tran, J. Windyga, D. Bonzo, C. Macie, J. Mahlangu

Hematology/Oncology Meeting Abstracts

Introduction: Eptacog beta (CEVENFACTA®) is a new rFVIIa approved by the EMA for the treatment of bleeding events and prevention of bleeding during surgery in persons with haemophilia A/B with inhibitors (PwHABI) aged ≥12 years (y).

Methods: PERSEPT 3 was a Phase 3 (NCT02020369) trial of eptacog beta in PwHABI who required surgical procedures. Eptacog beta was administered at an initial dose of 200μg/kg or 75μg/kg for major or minor procedures respectively. This was followed by 75μg/kg for ≥5 (major procedures) or ≥2 (minor procedures) days. Haemostatic efficacy was assessed using a 4-point scale during the intra and postoperative care …


A Randomized Phase 2 Study Of Trastuzumab And Pertuzumab (Tp) Compared To Cetuximab And Irinotecan (Cetiri) In Advanced/Metastatic Colorectal Cancer (Mcrc) With Her2 Amplification: Swog S1613, Kanwal P. S Raghav, Katherine A. Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T. Esparaz, Syed Mohammad A. Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, Philip A. Philip Feb 2023

A Randomized Phase 2 Study Of Trastuzumab And Pertuzumab (Tp) Compared To Cetuximab And Irinotecan (Cetiri) In Advanced/Metastatic Colorectal Cancer (Mcrc) With Her2 Amplification: Swog S1613, Kanwal P. S Raghav, Katherine A. Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T. Esparaz, Syed Mohammad A. Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, Philip A. Philip

Hematology/Oncology Meeting Abstracts

Background: HER2 (ERBB2) over-expression and amplification (HER2+) is seen in a small but distinct subset (2-3%) of mCRC and is enriched in RAS/BRAF wild type (WT) tumors. This subset is characterized by a limited response to anti-epidermal growth factor receptor monoclonal antibodybased (anti-EGFR) therapy and a promising response to dual-HER2 inhibition.

Methods: In this multicenter, open label, randomized, phase 2 trial, we enrolled 54 patients with RAS/BRAF WT HER2+ mCRC who had had disease progression after 1 or 2 previous therapies. HER2 status was confirmed centrally with immunohistochemistry (IHC) and in-situ hybridization (ISH). HER2+ was defined as IHC 3+ or …


Randomized, Phase Ii Selection Study Of Ramucirumab And Paclitaxel Versus Folfiri In Refractory Small Bowel Adenocarcinoma: Swog S1922, Michael J. Overman, Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, Philip A. Philip Feb 2023

Randomized, Phase Ii Selection Study Of Ramucirumab And Paclitaxel Versus Folfiri In Refractory Small Bowel Adenocarcinoma: Swog S1922, Michael J. Overman, Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, Philip A. Philip

Hematology/Oncology Meeting Abstracts

Background: Small bowel adenocarcinoma is a rare malignancy with limited evidence to support the choice of systemic chemotherapy beyond the frontline setting. Though second-line therapy has historically been extrapolated from colorectal cancers, recent molecular data has demonstrated small bowel adenocarcinoma to be genomically unique when compared to either colon or gastric cancer. Retrospective analyses of irinotecan- and taxane-based therapies and one prospective phase II clinical trial of nab-paclitaxel have demonstrated clinical activity in this cancer. Ramucirumab/paclitaxel represents an active combination in the management of gastric cancer. SWOG 1922 evaluates the use of FOLFIRI or ramucirumab/paclitaxel in the second- and later-line …


Swog 1815: A Phase Iii Randomized Trial Of Gemcitabine, Cisplatin, And Nab-Paclitaxel Versus Gemcitabine And Cisplatin In Newly Diagnosed, Advanced Biliary Tract Cancers, Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Carol Aghajanian, Benjamin R. Tan, Puneet S. Cheema, Anuj K. Patel, Renuka V. Iyer, Robin K. Kelley, Jaykumar R. Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Hochster, Philip A. Philip Feb 2023

Swog 1815: A Phase Iii Randomized Trial Of Gemcitabine, Cisplatin, And Nab-Paclitaxel Versus Gemcitabine And Cisplatin In Newly Diagnosed, Advanced Biliary Tract Cancers, Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Carol Aghajanian, Benjamin R. Tan, Puneet S. Cheema, Anuj K. Patel, Renuka V. Iyer, Robin K. Kelley, Jaykumar R. Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Hochster, Philip A. Philip

Hematology/Oncology Meeting Abstracts

Background: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Gemcitabine-based regimens are the standard of care in advanced disease, but median overall survival (OS) is roughly 12 months. The addition of albumin-bound paclitaxel to gemcitabine and cisplatin (GAP) demonstrated promising efficacy in a 60 patient, single-arm phase II study (Shroff et al, JAMA Oncol 2019), with observed median OS of 19.2 months.

Methods: SWOG 1815 is a randomized, open-label, phase III trial comparing GAP to gemcitabine/cisplatin (GC). The study included newly diagnosed advanced BTC patients (pts), randomized 2:1 to GAP vs. GC. GAP included …


Apollo: A Randomized Phase Ii Double-Blind Study Of Olaparib Versus Placebo Following Curative Intent Therapy In Patients With Resected Pancreatic Cancer And A Pathogenic Brca1, Brca2 Or Palb2 Mutation-Ecog-Acrin Ea2192, Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, Peter J. O'Dwyer Feb 2023

Apollo: A Randomized Phase Ii Double-Blind Study Of Olaparib Versus Placebo Following Curative Intent Therapy In Patients With Resected Pancreatic Cancer And A Pathogenic Brca1, Brca2 Or Palb2 Mutation-Ecog-Acrin Ea2192, Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, Peter J. O'Dwyer

Hematology/Oncology Meeting Abstracts

Background: A meaningful subset of PDAC is characterized by a homologous recombination deficiency (HRD). The most well-defined patients within this group are those with pathogenic variants in BRCA1, BRCA2 and PALB2. In the metastatic setting, PARP inhibitor maintenance provides a progression-free survival benefit after a period of platinum based chemotherapy1,2, but the role of PARP inhibitors in the curative intent setting is undefined. The OlympiA study established one year of olaparib as the standard of care for patients with BRCA-related, early stage breast cancer who completed all other curative-intent treatment3. Therefore, we have designed a randomized, phase II double-blind study …


Nrg Gi008: Colon Adjuvant Chemotherapy Based On Evaluation Of Residual Disease (Circulate-Us), Christopher H. Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, Arvind Dasari Feb 2023

Nrg Gi008: Colon Adjuvant Chemotherapy Based On Evaluation Of Residual Disease (Circulate-Us), Christopher H. Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, Arvind Dasari

Hematology/Oncology Meeting Abstracts

Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and may outperform traditional clinical and pathological features in prognosticating risk for recurrence. CC pts who do not have detectable ctDNA (ctDNA-) are at a much lower risk of recurrence and may be spared the toxicities associated with AC. Furthermore, for CC pts with detectable ctDNA (ctDNA+) who are at …


A Phase I Study Of Cpi-613 (Devimistat) In Combination With Chemoradiation In Patients With Pancreatic Adenocarcinoma, Mandana Kamgar, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed N. Al Hallak, Philip A. Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, William A. Hall Feb 2023

A Phase I Study Of Cpi-613 (Devimistat) In Combination With Chemoradiation In Patients With Pancreatic Adenocarcinoma, Mandana Kamgar, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed N. Al Hallak, Philip A. Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, William A. Hall

Hematology/Oncology Meeting Abstracts

Background: Local tumor progression is a cause of significant mortality and morbidity in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). Effective approaches to achieve durable local control are urgently needed. Metabolic reprogramming and enhanced mitochondrial function, both hallmarks of PDAC, are known contributors to chemo- and radio-resistance. CPI-613, a lipoic acid analog that selectively inhibits components of the Krebs cycle in tumors, showed promising preclinical synergy in combination with gemcitabine and radiation therapy (gem-RT).

Methods: We describe a single-arm, single-center, open-label, phase I study designed to determine the maximumtolerated dose of CPI-613 when used concomitantly with gemcitabine and intensity modulated …


Molecular Characterization And Clinical Outcomes Of Pancreatic Neuroendocrine Tumors (Pnens) Harboring Pak4-Nampt Alterations, Ibrahim Azar, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Moh'd M. Khushman, Heloisa P. Soares, Wafik S. El-Deiry, Philip A. Philip, Emil Lou, Alex P. Farrell, Jeffrey Swensen, Matthew J. Oberley, Jim Abraham, Chadi Nabhan, Sanjay Goel, Wolfgang M. Korn, Anthony F. Shields Feb 2023

Molecular Characterization And Clinical Outcomes Of Pancreatic Neuroendocrine Tumors (Pnens) Harboring Pak4-Nampt Alterations, Ibrahim Azar, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Moh'd M. Khushman, Heloisa P. Soares, Wafik S. El-Deiry, Philip A. Philip, Emil Lou, Alex P. Farrell, Jeffrey Swensen, Matthew J. Oberley, Jim Abraham, Chadi Nabhan, Sanjay Goel, Wolfgang M. Korn, Anthony F. Shields

Hematology/Oncology Meeting Abstracts

Background: The mTOR inhibitor, Everolimus (EVE), is FDA-approved for the treatment of advanced PNENs on the basis of delay of progression. The RADIANT-3 trial showed an increase in PFS from 4.6 to 11 months compared to placebo with an ORR of only 5%. Prior studies suggest that targeting the aberrant expression of mTOR regulators p21 activated kinase 4 (PAK4) and nicotinamide adenine dinucleotide biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT) in PNENs sensitizes these tumors to EVE. To further qualify these observations, we queried a large real-world dataset of PNENs, characterizing the molecular and immune landscapes, as well as the clinical outcomes …


World Transit Research February 2023 Newsletter, Institute Of Transport Studies Monash University Feb 2023

World Transit Research February 2023 Newsletter, Institute Of Transport Studies Monash University

World Transit Research Newsletter

No abstract provided.